Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Getinge AB's share price for the quarter that ended in Jun. 2026 was kr198.1. Getinge AB's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 272 Mil. Therefore, Getinge AB's market cap for the quarter that ended in Jun. 2026 was kr53,956 Mil.
Getinge AB's quarterly market cap
declined
from Dec. 2025 (kr59,595 Mil) to Mar. 2026 (kr51,355 Mil) but then
increased
from Mar. 2026 (kr51,355 Mil) to Jun. 2026 (kr53,956 Mil).
Getinge AB's annual market cap
declined
from Dec. 2023 (kr61,093 Mil) to Dec. 2024 (kr49,449 Mil) but then
increased
from Dec. 2024 (kr49,449 Mil) to Dec. 2025 (kr59,595 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Getinge AB's Enterprise Value for Today is kr71,827 Mil.
Getinge AB (OSTO:GETI B) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Getinge AB Market Cap Related Terms
Getinge AB Market Cap Historical Data
* Premium members only.
The historical data trend for Getinge AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:GETI B vs ABT, SYK, MDT: Market Cap Comparison
For the Medical Devices subindustry, Getinge AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Getinge AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Getinge AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getinge AB (OSTO:GETI B) has a Market Cap of kr62,727 Mil as of Jul. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Getinge AB and its competitors. According to the industry distribution chart, Getinge AB ranks #46 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 5.3%.
Is Getinge AB's Market Cap too high?
Getinge AB's current Market Cap is kr62,727 Mil. Based on the distribution chart, Getinge AB ranks #46 out of 863 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getinge AB has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #46 out of 863 companies for Market Cap. This places Getinge AB in the top 5% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 114.85, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 114.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current Market Cap is kr62,727 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (OSTO:GETI B) is currently considered Modestly Overvalued. The stock's GF Value™ is kr205.28, compared to a current price of kr230.30 — trading 12.2% above its estimated fair value. The current Market Cap is kr62,727 Mil. Getinge AB's overall GF Score™ is 81/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Getinge AB (OSTO:GETI B), the current Market Cap is kr62,727 Mil as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (OSTO:GETI B) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of kr230.30 is trading 12.2% above its estimated GF Value™ of kr205.28.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for OSTO:GETI B:
Market Cap: kr62,727 Mil
GF Value™: kr205.28 vs. price of kr230.30 (12.2% above fair value)
No single metric tells the full story. See the OSTO:GETI B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
81GF Score
Get the complete analysis for OSTO:GETI B
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GETI B has been successfully added to your 
